Literature DB >> 33570182

Cognitive performance as a predictor of healthcare transition in sickle cell disease.

Anjelica C Saulsberry-Abate1, Marita Partanen2, Jerlym S Porter3, Pradeep S B Podila4, Jason R Hodges1, Allison A King5, Winfred C Wang1, Jane E Schreiber6,7, Xiwen Zhao8, Guolian Kang8, Lisa M Jacola3, Jane S Hankins1.   

Abstract

Neurocognitive deficits in sickle cell disease (SCD) may impair adult care engagement. We investigated the relationship between neurocognitive functioning and socio-environmental factors with healthcare transition outcomes. Adolescents aged 15-18 years who had neurocognitive testing and completed a visit with an adult provider were included. Transition outcomes included transfer interval from paediatric to adult care and retention in adult care at 12 and 24 months. Eighty adolescents (59% male, 64% HbSS/HbSβ0 -thalassaemia) were included. Mean age at adult care transfer was 18·0 (±0·3) years and transfer interval was 2·0 (±2·3) months. Higher IQ (P = 0·02; PFDR  = 0·05) and higher verbal comprehension (P = 0·008; PFDR  = 0·024) were associated with <2 and <6 month transfer intervals respectively. Better performance on measures of attention was associated with higher adult care retention at 12 and 24 months (P = 0·009; PFDR  = 0·05 and P = 0·04; PFDR  = 0·12 respectively). Transfer intervals <6 months were associated with smaller households (P = 0·02; PFDR  = 0·06) and households with fewer children (P = 0·02; PFDR  = 0·06). Having a working parent was associated with less retention in adult care at 12 and 24 months (P = 0·01; P = 0·02 respectively). Lower IQ, verbal comprehension, attention difficulties and environmental factors may negatively impact transition outcomes. Neurocognitive function should be considered in transition planning for youth with SCD.
© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  health literacy; neurocognition; sickle cell disease; silent infarcts; socio-determinants of health; transition to adult care

Mesh:

Year:  2021        PMID: 33570182      PMCID: PMC8092972          DOI: 10.1111/bjh.17351

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  38 in total

Review 1.  Neurocognitive sequelae of pediatric sickle cell disease: a review of the literature.

Authors:  Leslie D Berkelhammer; Adrienne L Williamson; Stacy D Sanford; Courtney L Dirksen; William G Sharp; Allison S Margulies; Rebecca A Prengler
Journal:  Child Neuropsychol       Date:  2007-03       Impact factor: 2.500

2.  Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis.

Authors:  Michael R DeBaun; Djamila L Ghafuri; Mark Rodeghier; Poulami Maitra; Shruti Chaturvedi; Adetola Kassim; Kenneth I Ataga
Journal:  Blood       Date:  2018-12-10       Impact factor: 22.113

3.  Pediatric to adult care co-location transitional model for youth with sickle cell disease.

Authors:  Vikki G Nolan; Sheila M Anderson; Matthew P Smeltzer; Jerlym S Porter; Yvonne M Carroll; Ian M Brooks; Nada Elmagboul; James G Gurney; Jane S Hankins
Journal:  Am J Hematol       Date:  2017-11-10       Impact factor: 10.047

4.  Attention difficulties are associated with lower engagement in adult care amongst youth with sickle cell disease.

Authors:  Jeanelle S Ali; Frank Andrasik; Kristoffer S Berlin; Jerlym Porter; Jane Hankins; Sheila Anderson; Jane E Schreiber
Journal:  Br J Haematol       Date:  2020-02-26       Impact factor: 6.998

Review 5.  Neurocognitive aspects of pediatric sickle cell disease.

Authors:  R T Brown; F D Armstrong; J R Eckman
Journal:  J Learn Disabil       Date:  1993-01

6.  Acute care utilization and rehospitalizations for sickle cell disease.

Authors:  David C Brousseau; Pamela L Owens; Andrew L Mosso; Julie A Panepinto; Claudia A Steiner
Journal:  JAMA       Date:  2010-04-07       Impact factor: 56.272

7.  Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia.

Authors:  Elliott P Vichinsky; Lynne D Neumayr; Jeffrey I Gold; Michael W Weiner; Randall R Rule; Diana Truran; Jeffrey Kasten; Barry Eggleston; Karen Kesler; Lillian McMahon; Eugene P Orringer; Thomas Harrington; Karen Kalinyak; Laura M De Castro; Abdullah Kutlar; Cynthia J Rutherford; Cage Johnson; Joel David Bessman; Lanetta B Jordan; F Daniel Armstrong
Journal:  JAMA       Date:  2010-05-12       Impact factor: 56.272

8.  Working Memory in Children With Neurocognitive Effects From Sickle Cell Disease: Contributions of the Central Executive and Processing Speed.

Authors:  Kelsey E Smith; Jeffrey Schatz
Journal:  Dev Neuropsychol       Date:  2016-10-19       Impact factor: 2.253

9.  Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.

Authors:  Poulami Maitra; Melissa Caughey; Laura Robinson; Payal C Desai; Susan Jones; Mehdi Nouraie; Mark T Gladwin; Alan Hinderliter; Jianwen Cai; Kenneth I Ataga
Journal:  Haematologica       Date:  2017-01-19       Impact factor: 9.941

10.  Impact of a paediatric-adult care transition programme on the health status of patients with sickle cell disease: study protocol for a randomised controlled trial (the DREPADO trial).

Authors:  Delphine Hoegy; Nathalie Bleyzac; Alexandra Gauthier-Vasserot; Giovanna Cannas; Angélique Denis; Arnaud Hot; Yves Bertrand; Pauline Occelli; Sandrine Touzet; Claude Dussart; Audrey Janoly-Dumenil
Journal:  Trials       Date:  2020-02-10       Impact factor: 2.279

View more
  2 in total

Review 1.  Chronic pediatric diseases and risk for reading difficulties: a narrative review with recommendations.

Authors:  Donna Perazzo; Ryan Moore; Nadine A Kasparian; Megan Rodts; Tzipi Horowitz-Kraus; Lori Crosby; Brian Turpin; Andrew F Beck; John Hutton
Journal:  Pediatr Res       Date:  2022-02-04       Impact factor: 3.953

2.  The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains.

Authors:  Macy L Early; Elizabeth Linton; Allison Bosch; Timothy Campbell; Felicia Hill-Briggs; Lydia H Pecker; Eboni I Lance; Sophie Lanzkron
Journal:  Br J Haematol       Date:  2022-04-06       Impact factor: 8.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.